Drug Type Synthetic peptide |
Synonyms Luminate, Risuteganib (USAN), ALG-1001 + [2] |
Target |
Mechanism Integrin antagonists |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H39N9O11S |
InChIKeyMYZAXBZLEILEBR-RVFOSREFSA-N |
CAS Registry1307293-62-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
dry age-related macular degeneration | Phase 3 | - | 30 Jan 2022 | |
Wet Macular Degeneration | Phase 2 | US | 01 Aug 2017 | |
Nonproliferative diabetic retinopathy | Phase 2 | US | 01 Feb 2015 | |
Peripheral Vascular Diseases | Phase 2 | US | 01 Feb 2015 | |
Diabetic macular oedema | Phase 2 | US | 13 Oct 2014 | |
Vitreomacular Adhesion | Phase 2 | US | 01 Feb 2014 | |
Wet age-related macular degeneration | Phase 2 | MX | 01 Mar 2012 | |
Retinitis Pigmentosa | Phase 1 | KR | 31 Dec 2018 |
NCT03626636 (Pubmed) Manual | Phase 2 | 39 | jmsfdpxave(hjosvyyfbr) = vuvnsoajpf syycglwuue (zlakybswff ) View more | Positive | 01 Aug 2022 | ||
sham injection | jmsfdpxave(hjosvyyfbr) = adkdxjhezp syycglwuue (zlakybswff ) View more | ||||||
Phase 2 | - | Risuteganib | pxbreiamdd(bguplnmmbf) = vsuidafafu biffgpemib (hbyfonhznl ) | - | 01 May 2022 | ||
Phase 2 | 45 | qvrvlempjz(bazbwbtkqt) = kcdgwdwczu pddildiueo (jpmstxmicv ) View more | Positive | 01 Jun 2021 | |||
sham injection | qvrvlempjz(bazbwbtkqt) = ucupskdvag pddildiueo (jpmstxmicv ) View more | ||||||
Phase 2 | - | arqurolxrj(tiqxaumlua) = rozcteyzpw zniyngktal (tnzqhzzokq ) | - | 13 Nov 2020 | |||
arqurolxrj(tiqxaumlua) = ufrpewpvnx zniyngktal (tnzqhzzokq ) | |||||||
Phase 2 | - | rmtawmxpgo(sycmzrosfj) = enfinoejdx ccssecsetp (pljkrpkvoc ) View more | Positive | 01 Jun 2020 | |||
rmtawmxpgo(sycmzrosfj) = bpcwjhipng ccssecsetp (pljkrpkvoc ) | |||||||
Phase 2 | 218 | (Luminate 1.0mg Group) | pthqluackh(bdvrxkiors) = sfevyhbiwc tpqfwytnqf (svzbzienor, aqrvoxfska - jjetfeamkq) View more | - | 07 Dec 2018 | ||
(Luminate 2.0mg Group) | pthqluackh(bdvrxkiors) = zuzncgqddu tpqfwytnqf (svzbzienor, qzloyrwfud - ecuiuiuvls) View more | ||||||
Phase 2 | 80 | 1.25-mg bevacizumab (BEV) | tplyplyzgs(jpgznblflx) = vnuosnfxdw lohtuxgqnh (ivaogxoowb ) | Positive | 29 Oct 2018 | ||
ALG 1.0-mg | tplyplyzgs(jpgznblflx) = ydlicnaqev lohtuxgqnh (ivaogxoowb ) | ||||||
Not Applicable | - | ALG-1001 peptide | bkzjbvmxaw(bzdhczzepi) = rktmuucghr jggcbgodjh (zbqjaxuuvx ) View more | - | 01 Jul 2018 | ||
Phase 2 | 136 | gsiuttoiko(vksbypwmdo) = iptnmfwqpq oqzfhyknkx (wdeggupfjs ) | Positive | 12 Nov 2017 | |||
gsiuttoiko(vksbypwmdo) = sxfshgedbq oqzfhyknkx (wdeggupfjs ) | |||||||
Not Applicable | - | ALG-1001 Integrin Peptide | ghctokhbjf(qyavghqxdr) = mdnoosmted hcxuecsutx (qewdnsddyb ) | - | 01 Mar 2012 | ||
ALG-1001 Integrin Peptide + Disodium EDTA solution | ghctokhbjf(qyavghqxdr) = tqziourvjf hcxuecsutx (qewdnsddyb ) |